An Open Label, Non-Comparative, Multicenter, Phase III Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infections

NCT00001810 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

300

Enrollment

NIH

Sponsor class

Conditions

Aspergillosis
Candidiasis
Fungemia
Mycoses

Interventions

DRUG: Voriconazole

Sponsor

National Cancer Institute (NCI)